Average Insider

Where insiders trade, we follow

$ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Healthcare
Sector
Biotechnology
Industry
Chad Robins
CEO
619
Employees
$29.04
Current Price
$2.45B
Market Cap
52W Low$12.00
Current$29.0484.3% above low, 15.7% below high
52W High$32.21

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells27$1,458,024.7648,984
2 weeksBuys00--All Sells
Sells218$3,078,971.17108,389
1 monthBuys00--All Sells
Sells238$6,473,836.79239,080
2 monthsBuys00--All Sells
Sells361$11,204,631.12414,888
3 monthsBuys00--All Sells
Sells465$14,724,890.19541,104
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 11, 2026
RUBINSTEIN JULIE
President and COO
Sale6,898$31.22$215,355.56View Details
Nov 13, 2026
RUBINSTEIN JULIE
President and COO
Sale11,466$28.93$331,711.38View Details
Nov 11, 2026
RUBINSTEIN JULIE
President and COO
Sale4,983$30.29$150,935.07View Details
Nov 12, 2026
RUBINSTEIN JULIE
President and COO
Sale11,881$29.40$349,301.40View Details
Nov 11, 2026
BOBULSKY SUSAN
Chief Commercial Officer, MRD
Sale1,875$32.00$60,000.00View Details
Nov 10, 2026
RUBINSTEIN JULIE
President and COO
Sale9,981$29.35$292,942.35View Details
Nov 9, 2026
RUBINSTEIN JULIE
President and COO
Sale8,381$30.15$252,687.15View Details
Nov 9, 2026
RUBINSTEIN JULIE
President and COO
Sale1,100$28.87$31,757.00View Details
Nov 10, 2026
RUBINSTEIN JULIE
President and COO
Sale1,900$30.41$57,779.00View Details
Nov 9, 2026
RUBINSTEIN JULIE
President and COO
Sale2,400$30.58$73,392.00View Details
Nov 5, 2026
RUBINSTEIN JULIE
President and COO
Sale5,455$26.88$146,630.40View Details
Nov 5, 2026
RUBINSTEIN JULIE
President and COO
Sale5,926$26.10$154,668.60View Details
Nov 6, 2026
RUBINSTEIN JULIE
President and COO
Sale8,400$27.32$229,488.00View Details
Nov 4, 2026
RUBINSTEIN JULIE
President and COO
Sale7,881$26.60$209,634.60View Details
Nov 5, 2026
RUBINSTEIN JULIE
President and COO
Sale500$27.70$13,850.00View Details
Nov 4, 2026
RUBINSTEIN JULIE
President and COO
Sale4,000$25.78$103,120.00View Details
Nov 6, 2026
RUBINSTEIN JULIE
President and COO
Sale3,481$27.88$97,050.28View Details
Nov 2, 2026
RUBINSTEIN JULIE
President and COO
Sale2,585$26.34$68,088.90View Details
Nov 2, 2026
RUBINSTEIN JULIE
President and COO
Sale9,296$25.23$234,538.08View Details
Oct 30, 2026
RUBINSTEIN JULIE
President and COO
Sale9,486$26.55$251,853.30View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 4, 2026
EPS
Estimated-$0.09
ActualN/A
Revenue
Estimated$71.57M
ActualN/A
4 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.10.12